RELMADA THERAPEUTICS, INC. (RLMD) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $106.67K; Additional Paid in CapitalUSD $936.68M; Retained Earnings (Accumulated Deficit)USD $-730.23M; Stockholders' Equity Attributable to ParentUSD $206.56M.
- 2026-03-31: Common Stock, Value, IssuedUSD $104.89K; Additional Paid in CapitalUSD $935.95M; Retained Earnings (Accumulated Deficit)USD $-717.32M; Stockholders' Equity Attributable to ParentUSD $218.73M.
- 2025-12-31: Common Stock, Value, IssuedUSD $73.33K; Additional Paid in CapitalUSD $784.71M; Retained Earnings (Accumulated Deficit)USD $-698.27M; Stockholders' Equity Attributable to ParentUSD $86.51M.
- 2025-09-30: Common Stock, Value, IssuedUSD $33.19K; Additional Paid in CapitalUSD $687.83M; Retained Earnings (Accumulated Deficit)USD $-678.40M; Stockholders' Equity Attributable to ParentUSD $9.47M.
RELMADA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Treasury Stock, Common, Value USD | Retained Earnings, Appropriated USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Common, Shares shares | Adjustments to Additional Paid in Capital, Warrant Issued USD | Common Stocks, Including Additional Paid in Capital USD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $106.67K | $936.68M | $-730.23M | $206.56M | 3 month · $199.88K | 3 month · $902.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $104.89K | $935.95M | $-717.32M | $218.73M | (m) | 3 month · $956.19K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $73.33K | $784.71M | $-698.27M | $86.51M | (m) | 12 month · $13.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $33.19K | $687.83M | $-678.40M | $9.47M | (m) | 3 month · $3.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $33.19K | $684.22M | $-668.31M | $15.95M | (m) | 3 month · $3.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $33.19K | $680.85M | $-658.44M | $22.44M | (m) | 3 month · $3.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $30.17K | $676.37M | $-640.88M | $35.52M | (m) | 12 month · $30.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $30.17K | $669.82M | $-622.22M | $47.63M | (m) | 3 month · $7.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $30.17K | $661.96M | $-600.50M | $61.49M | (m) | 3 month · $7.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $30.17K | $654.75M | $-582.73M | $72.05M | (m) | 3 month · $8.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $30.10K | $646.23M | $-560.90M | $85.36M | (m) | 12 month · $43.81M | (m) | $560.90M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $30.10K | $636.43M | $-535.74M | $100.73M | (m) | 3 month · $11.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $30.10K | $625.04M | $-513.74M | $111.34M | (m) | 3 month · $11.17M | (m) | $513.74M | (m) | (m) | (m) | (m) | 3 month · $11.17M |
| 2023-03-31 | $30.10K | $613.87M | $-488.43M | $125.47M | (m) | 3 month · $11.35M | (m) | $488.43M | (m) | (m) | (m) | (m) | 3 month · $11.35M |
| 2022-12-31 | $30.10K | $602.52M | $-462.11M | $140.44M | (m) | 12 month · $44.19M | (m) | $462.11M | (m) | (m) | 12 month · $1.26M | (m) | (m) |
| 2022-09-30 | $28.64K | $590.48M | $-424.17M | $166.34M | (m) | (m) | (m) | (m) | $166.34M | (m) | (m) | (m) | 3 month · $8.34M |
| 2022-09-20 | (m) | (m) | (m) | (m) | (m) | (m) | $1.45M | (m) | (m) | 1.45M | (m) | (m) | (m) |
| 2022-06-30 | $30.02K | $581.57M | $-384.75M | $196.85M | 3 month · $13.15M | (m) | (m) | (m) | $196.85M | (m) | (m) | (m) | 3 month · $12.30M 15 month · $12.30M |
| 2022-04-08 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 484.90K | (m) | (m) | (m) |
| 2022-03-31 | $29.40K | $555.18M | $-344.81M | $210.40M | (m) | (m) | (m) | (m) | $210.40M | (m) | (m) | (m) | 3 month · $11.93M |
| 2022-03-14 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 2 month · $110.00K |
| 2021-12-31 | $27.74K | $513.30M | $-305.07M | $208.26M | (m) | (m) | (m) | (m) | $208.26M | (m) | 12 month · $23.42M | (m) | 12 month · $40.49M |
| 2021-09-30 | $17.50K | $343.36M | $-270.69M | $72.69M | (m) | (m) | (m) | (m) | $72.69M | (m) | (m) | (m) | 3 month · $8.01M |
| 2021-06-30 | $17.47K | $324.92M | $-228.08M | $96.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $8.27M |
| 2021-03-31 | $16.75K | $292.66M | $-201.53M | $91.15M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $5.85M |
| 2020-12-31 | $16.33K | $284.88M | $-179.32M | $105.58M | (m) | (m) | (m) | (m) | $105.58M | (m) | (m) | (m) | 12 month · $20.78M |
| 2020-09-30 | $16.19K | $280.75M | $-158.55M | $122.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $5.24M |
| 2020-06-30 | $15.85K | $273.87M | $-141.65M | $132.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $7.30M |
| 2020-03-31 | $14.94K | $243.68M | $-130.53M | $113.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $5.04M |
| 2019-12-31 | $14.46K | $235.52M | $-119.86M | $115.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $2.37M |
| 2019-09-30 | $9.94K | $121.30M | $-115.33M | $5.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $757.72K |
| 2019-06-30 | $9.74K | $119.27M | $-111.66M | $7.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $403.46K 12 month · $1.21M |
| 2019-03-31 | $30.98K | $107.98M | $-107.54M | $473.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $394.69K |
| 2018-12-31 | $29.76K | $106.26M | $-104.85M | $1.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $263.04K 6 month · $415.85K |
| 2018-09-30 | $12.55K | $88.97M | $-97.72M | $-8.68M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $152.80K |
| 2018-06-30 | $3.14K | $88.83M | $-94.34M | $-5.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $518.00K |
| 2018-03-31 | $12.55K | $88.67M | $-90.99M | $-2.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $162.26K |
| 2017-12-31 | $12.54K | $88.50M | $-87.79M | $721.16K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $134.04K |
| 2017-09-30 | $12.54K | $87.82M | $-86.37M | $1.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $68.87K |
| 2017-06-30 | $12.53K | $86.83M | $-85.38M | $1.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $704.45K |
| 2017-03-31 | $12.04K | $86.54M | $-83.75M | $2.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $12.04K | $86.43M | $-81.77M | $4.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $12.04K | $86.30M | $-80.74M | $5.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $12.04K | $86.13M | $-79.10M | $7.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $12.02K | $85.97M | $-75.78M | $10.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $12.00K | $85.67M | $-73.92M | $11.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $11.01K | $85.28M | $-71.46M | $13.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $10.78K | $84.92M | $-76.12M | $8.81M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $15.30M | (m) | (m) |
| 2015-03-31 | $53.73K | $84.60M | $-82.16M | $2.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $53.68K | $84.24M | $-79.70M | $4.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $43.85K | $64.39M | (m) | $-20.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $8.06K | $54.20M | $-55.32M | $-1.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $498.78K | $14.25M | (m) | $-11.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-02-28 | $28.50K | $15.00K | (m) | $-31.16K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $4.96K | $16.01M | (m) | $-17.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-11-30 | $28.50K | $15.00K | (m) | $-28.03K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-08-31 | $28.50K | $15.00K | (m) | $-13.66K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-05-31 | $23.50K | (m) | (m) | $-21.29K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-02-28 | $23.50K | (m) | (m) | $-1.81K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $240.24K | $9.31M | (m) | $-3.71M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-08-31 | $23.50K | (m) | (m) | $11.36K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-04-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.01M | (m) |
| 2011-12-31 | (m) | (m) | (m) | $-2.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-08-31 | (m) | (m) | (m) | $9.91K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | $-2.11M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | $-1.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | $-187.93K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | $1.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | (m) | $-2.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2005-12-31 | (m) | (m) | (m) | $-1.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2004-12-31 | (m) | (m) | (m) | $-805.73K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |